Abstracts tagged "radiography and treatment"

Abstract Number: 716 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors
Susanne Juhl Pedersen¹, Ulrich Weber², Roula Said Nahal³, Inge Juul Sorensen¹, Anne Gitte Loft⁴, Niels Tvede¹, Gina Kollerup¹, Lars Juul¹, Gorm Thamsborg¹, Ole Rintek Madsen¹, Jakob M. Møller⁵, Lone Balding⁶, Anne Grethe Jurik⁷ and Mikkel Østergaard⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ³Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ⁷Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark
Background/Purpose: Only few studies have investigated long-term radiographic progression in the spine of patients with ankylosing spondylitis (AS). Moreover, no studies have reported changes in…
Abstract Number: 3210 • 2016 ACR/ARHP Annual Meeting
10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes
Merete Lund Hetland¹, Kristian Stengaard-Pedersen², Peter Junker¹, Hanne Lindegaard¹, Torkell Ellingsen¹, Jan Pødenphant², Henrik Skjødt¹, Aage Vestergaard², Bo Jannik Ejbjerg¹, Søren Jacobsen¹, Niels Steen Krogh¹, Mikkel Ostergaard¹ and Kim Hørslev-Petersen², ¹Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Glostrup, Denmark, ²Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark
Background/Purpose: Few RCTs have investigated long-term (10+ years) outcomes of goal-directed synovitis suppression in early rheumatoid arthritis (RA). The CIMESTRA trial was a 2-year double-blinded…
Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Désirée van der Heijde¹, Robert B. M. Landewé², Philip J. Mease³, Iain B. McInnes⁴, Philip G. Conaghan⁵, Luminita Pricop⁶, Gregory Ligozio⁷, Hanno Richards⁸ and Shephard Mpofu⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…
Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Mami Tamai^1,2, Yoshikazu Nakashima³, Junko Kita⁴, Ayuko Takatani⁴, Ayako Nishino³, Takahisa Suzuki³, Yoshiro Horai³, Akitomo Okada⁵, Shin-ya Kawashiri^3,6, Naoki Iwamoto³, Kunihiro Ichinose³, Kazuhiko Arima⁶, Hideki Nakamura³, Tomoki Origuchi⁷, Masataka Uetani⁸, Katsumi Eguchi⁹ and Atsushi Kawakami³, ¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ²Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].